DEF: Intelligent Bio Solutions Seeks Stockholder Approval for Incentive Plan Amendment at 2025 Annual Meeting

Intelligent Bio Solutions Inc. is soliciting proxies for its Annual Meeting of Stockholders to be held on May 8, 2025, including a proposal to amend its 2019 Long Term Incentive Plan.

Summary

• Intelligent Bio Solutions Inc. will hold its Annual Meeting of Stockholders virtually on May 8, 2025.
• Stockholders of record as of March 18, 2025, are entitled to vote.
• The meeting will address the election of four directors, ratification of the appointment of UHY LLP as the company's independent auditor, and an amendment to the 2019 Long Term Incentive Plan.
• The proposed amendment to the 2019 Plan includes increasing the number of shares authorized for issuance by 2,366,666 and increasing the limit on shares underlying awards to non-employee directors to 50,000 per year.
• A proposal to authorize adjournment of the meeting, if necessary, to solicit additional proxies for the 2019 Plan Amendment Proposal will also be voted on.
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are aimed at improving the company's ability to attract and retain talent, which is a positive sign.

Positives

• The proposed amendment to the 2019 Long Term Incentive Plan aims to attract, retain, and reward directors, officers, and other employees.
• The company has a Code of Ethics in place that applies to all officers, directors, and employees.
• The Board of Directors has determined that each of the director nominees is an independent director.
• The Audit Committee has procedures in place for the pre-approval of audit and non-audit services rendered by the company's independent registered public accounting firm.

Negatives

• The company incurred costs of $50,000 plus expenses for engaging Alliance Advisors to solicit proxies.
• The company had a change in accounting firms, with BDO resigning and UHY being appointed as the independent registered public accounting firm.

Risks

• If the Annual Meeting is convened and a quorum is present, but there are not sufficient votes to approve Proposal 3, one or more of our proxy holders may move to adjourn the Annual Meeting at that time in order to enable our Board to solicit additional proxies.
• The company's success depends on attracting, retaining, and rewarding directors, officers, and other employees, and failure to do so could negatively impact the company's performance.

Future Outlook

The company is seeking stockholder approval for several proposals, including an amendment to the 2019 Long Term Incentive Plan, which is intended to attract, retain, and reward key personnel.

Industry Context

Companies in the medical device and product industries often use equity-based compensation to attract and retain talent, aligning employee incentives with shareholder value. The proposed amendment to the 2019 Long Term Incentive Plan is consistent with this practice.

Comparison to Industry Standards

• Many companies in the biotech and medical device industries utilize long-term incentive plans to attract and retain key employees.
• Increasing the share reserve and director award limits is a common practice to ensure the plan remains effective.
• Comparable companies such as [Competitor A] and [Competitor B] also have similar equity compensation plans in place.
• The specific terms of the plan, such as vesting schedules and performance metrics, are tailored to the company's specific circumstances and goals.

Related Party Transactions

• Spiro Sakiris, the Chief Financial Officer, purchased 112,727 units in the October 2023 Offering on the same terms as other purchasers.
• Christopher Towers, a former member of the Board, purchased 9,090 units in the October 2023 Offering on the same terms as other purchasers.

Stakeholder Impact

• Approval of the 2019 Plan Amendment Proposal could benefit employees, officers, directors, and consultants by providing them with equity-based compensation.
• Stockholders could benefit from the company's ability to attract and retain key personnel, which could lead to improved performance.
• The selection of UHY LLP as the independent auditor aims to ensure the accuracy and reliability of the company's financial statements.

Next Steps

• Stockholders should review the proxy statement and vote on the proposals.
• The company will hold the Annual Meeting on May 8, 2025, to vote on the proposals.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Incentive Plan, Director Election, Auditor Ratification, UHY LLP, 2019 Plan Amendment, Corporate Governance, Executive Compensation, Related Party Transactions